Lactoferrin - Pharming

Drug Profile

Lactoferrin - Pharming

Alternative Names: GPX 400; hLF

Latest Information Update: 30 Dec 2008

Price : $50

At a glance

  • Originator Pharming Group NV
  • Class Adjuvants; Antibacterials; Antifungals; Glycoproteins; Iron binding proteins
  • Mechanism of Action Chelating agents; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Bacterial infections; Cardiovascular disorders; Eye disorders; Haemorrhage; Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Mar 2005 Pharming and ProBio and Infigen have entered into an agreement for lactoferrin
  • 28 Oct 2003 Lactoferrin is no longer licensed to AM-Pharma Holding
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top